| Name | 4-(4-methylpiperazin-1-yl)benzaldehyde |
|---|---|
| Synonyms |
MFCD00452233
1-(4-Formylphenyl)-4-methylpiperazine 4-(4-Methylpiperazinyl)benzaldehyde 4-(4-Methyl-piperazin-1-yl)-benzaldehyde 4-(4-Methylpiperazin-1-yl)benzaldehyde 4-(4-Methyl-1-piperazinyl)benzaldehyde Benzaldehyde, 4-(4-methyl-1-piperazinyl)- |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 351.3±37.0 °C at 760 mmHg |
| Melting Point | 57 °C |
| Molecular Formula | C12H16N2O |
| Molecular Weight | 204.268 |
| Flash Point | 155.5±18.9 °C |
| Exact Mass | 204.126266 |
| PSA | 23.55000 |
| LogP | 1.28 |
| Vapour Pressure | 0.0±0.8 mmHg at 25°C |
| Index of Refraction | 1.581 |
| Hazard Codes | C: Corrosive; |
|---|---|
| Risk Phrases | R36/37/38 |
| Safety Phrases | S26-S36/37/39-S24/25 |
| HS Code | 2933599090 |
|
~90%
27913-99-1 |
| Literature: COLEY PHARMACEUTICAL GROUP, INC. Patent: WO2008/152471 A1, 2008 ; Location in patent: Page/Page column 38-39 ; |
|
~61%
27913-99-1 |
| Literature: RVX Therapeutics Inc.; McLure, Kevin G.; Young, Peter Ronald Patent: US2013/281397 A1, 2013 ; Location in patent: Paragraph 0523; 0524 ; |
|
~81%
27913-99-1 |
| Literature: Liu, Xiaoling; Go, Mei-Lin Bioorganic and Medicinal Chemistry, 2007 , vol. 15, # 22 p. 7021 - 7034 |
|
~%
27913-99-1 |
| Literature: Watanabe, Toshihiro; Kakefuda, Akio; Kinoyama, Isao; Takizawa, Kenji; Hirano, Seiko; Shibata, Hiroshi; Yanagisawa, Isao Chemical and Pharmaceutical Bulletin, 1997 , vol. 45, # 9 p. 1458 - 1469 |
|
~%
27913-99-1 |
| Literature: Welfide Corporation Patent: US6288061 B1, 2001 ; |
|
~%
27913-99-1 |
| Literature: Watanabe, Toshihiro; Kakefuda, Akio; Kinoyama, Isao; Takizawa, Kenji; Hirano, Seiko; Shibata, Hiroshi; Yanagisawa, Isao Chemical and Pharmaceutical Bulletin, 1997 , vol. 45, # 9 p. 1458 - 1469 |
|
~%
27913-99-1 |
| Literature: RVX Therapeutics Inc.; McLure, Kevin G.; Young, Peter Ronald Patent: US2013/281397 A1, 2013 ; |
| Precursor 8 | |
|---|---|
| DownStream 3 | |
| HS Code | 2933599090 |
|---|---|
| Summary | 2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |